Benitec Biopharma (BNTC) Competitors $12.62 -0.87 (-6.45%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$12.62 +0.01 (+0.04%) As of 07/8/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTC vs. EWTX, MESO, TVTX, CVAC, CALT, GPCR, HROW, PAHC, ABCL, and NTLAShould you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Edgewise Therapeutics (EWTX), Mesoblast (MESO), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Benitec Biopharma vs. Its Competitors Edgewise Therapeutics Mesoblast Travere Therapeutics CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Harrow Phibro Animal Health AbCellera Biologics Intellia Therapeutics Benitec Biopharma (NASDAQ:BNTC) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Which has better valuation and earnings, BNTC or EWTX? Benitec Biopharma has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K4,140.94-$21.75M-$1.51-8.36Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.40 Which has more volatility & risk, BNTC or EWTX? Benitec Biopharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Do analysts recommend BNTC or EWTX? Benitec Biopharma currently has a consensus price target of $23.83, suggesting a potential upside of 88.85%. Edgewise Therapeutics has a consensus price target of $40.00, suggesting a potential upside of 207.22%. Given Edgewise Therapeutics' higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is BNTC or EWTX more profitable? Edgewise Therapeutics' return on equity of -30.95% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% Edgewise Therapeutics N/A -30.95%-29.45% Does the media favor BNTC or EWTX? In the previous week, Edgewise Therapeutics had 10 more articles in the media than Benitec Biopharma. MarketBeat recorded 14 mentions for Edgewise Therapeutics and 4 mentions for Benitec Biopharma. Edgewise Therapeutics' average media sentiment score of 0.62 beat Benitec Biopharma's score of 0.54 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of BNTC or EWTX? 52.2% of Benitec Biopharma shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryBenitec Biopharma beats Edgewise Therapeutics on 8 of the 14 factors compared between the two stocks. Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNTC vs. The Competition Export to ExcelMetricBenitec BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$354.12M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-8.3620.8027.0020.10Price / Sales4,140.94286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book2.707.487.985.56Net Income-$21.75M-$55.04M$3.16B$248.40M7 Day Performance-0.94%2.44%2.40%4.67%1 Month Performance-21.95%1.90%2.19%6.64%1 Year Performance36.88%4.35%33.82%21.31% Benitec Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNTCBenitec Biopharma2.1412 of 5 stars$12.62-6.4%$23.83+88.9%+30.5%$354.12M$80K-8.3620News CoverageAnalyst ForecastEWTXEdgewise Therapeutics2.6298 of 5 stars$12.61-3.2%$40.00+217.2%-37.8%$1.37BN/A-8.1460MESOMesoblast1.9664 of 5 stars$10.53-1.4%$18.00+70.9%+35.2%$1.36B$5.90M0.0080Gap UpTVTXTravere Therapeutics3.3195 of 5 stars$14.60-2.7%$32.14+120.2%+75.5%$1.33B$233.18M-5.20460CVACCureVac4.4998 of 5 stars$5.41-0.7%$6.83+26.3%+73.2%$1.22B$579.18M5.88880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.6717 of 5 stars$18.73-8.0%$76.17+306.7%-49.7%$1.17BN/A-21.53136Positive NewsHROWHarrow2.5561 of 5 stars$31.36-1.2%$61.40+95.8%+38.1%$1.16B$199.61M-56.00180Positive NewsPAHCPhibro Animal Health3.673 of 5 stars$29.90+6.8%$24.40-18.4%+71.9%$1.13B$1.02B38.331,940News CoverageAnalyst UpgradeHigh Trading VolumeABCLAbCellera Biologics2.5473 of 5 stars$4.03+6.1%$7.50+86.1%+41.5%$1.13B$28.83M-7.20500News CoverageAnalyst ForecastHigh Trading VolumeNTLAIntellia Therapeutics4.6881 of 5 stars$10.25-4.6%$33.37+225.5%-51.5%$1.11B$57.88M-1.96600 Related Companies and Tools Related Companies EWTX Alternatives MESO Alternatives TVTX Alternatives CVAC Alternatives CALT Alternatives GPCR Alternatives HROW Alternatives PAHC Alternatives ABCL Alternatives NTLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNTC) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
